FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: ovarian cancer

Sort
E.g., 2013-05-20
E.g., 2013-05-20
Enter a comma separated list of user names.

(VRML, CRWE, DRJ, ECYT) PennyOmega.com Stocks In Action
Posted by pennylynnomega on April 16th, 2012

chartstockalert

Read More
comment 0
Share
Tags:
Merck, Crown Equity Holdings, CRWE, otc:crwe, ovarian cancer, AMEX:DRJ, DRJ, Dreams Inc, NASDAQ:VRML, Vermillion, VRML, Endocyte, NASDAQ:ECYT, ECYT, Stocks in Action, vintafolide, cell lung cancer, etarfolatide, pegylated liposomal doxorubicin

(LLNW, AEZS, BKS) PennyOmega.com Stocks In Action
Posted by pennylynnomega on August 30th, 2011

** Barnes & Noble (BKS) posted $1.4 billion in total sales for the first quarter 2012, a 2% increase compared to the prior year.

*********************

** Limelight Networks (LLNW) reported the sale of its EyeWonder rich media advertising unit to DG FastChannel for approximately $66 million.

*********************

Read More
comment 0
Share
Tags:
bks, LLNW, aezs, ovarian cancer, prostate cancer, NYSE:BKS, colorectal cancer, Limelight Networks, AEterna Zentaris, Aeterna, multiple myeloma, Stocks in Action, Adult Growth Hormone Deficiency, Barnes and Noble, bladder cancer, endometrial cancer

(ENMD, SGAE) PennyOmega.com Watch List for Monday June 06, 2011
Posted by pennylynnomega on June 5th, 2011

EntreMed (ENMD) reported clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.

The trial was an open-label, single-arm, multi-center-study of ENMD-2076 dosed orally as a single agent in patients with platinum-resistant recurrent ovarian, peritoneal or tubal cancer.

Read More
comment 0
Share
Tags:
ovarian cancer, EntreMed, NASDAQ:ENMD, SGAE, Siga Resources, Big Rock Resources, Lucky Thirteen gold placer, SGAE.OB, ENMD-2076, Canadian Pacific Rail, Lucky Thirteen Placer, multiple myeloma, OTC:SGAE, platinum resistant ovarian cancer, solid tumor cancers, Trans-Canada Highway

Access Pharma Aiming to Aid in Ovarian Cancer Fight
Posted by EmergingBiotechs on April 9th, 2011

There has been new research announced in an article on Bloomberg's Business Week that discusses mutated genes and the impact on the likelihood of getting ovarian cancer. In this arena, neurotoxicity in therapies has also been a constant bane in the side of researchers, drug manufacturers (and, subsequently, patients).

Read More
comment 0
Share
Tags:
ACCP, chemotherapy, ovarian cancer, Access Pharmaceuticals, ACCP.OB, ProLindac, $ACCP, neurotoxicity, oxaliplatin, Eloxatin, DAHC platinum, BRCA1, BRCA2

PWRM, MYRX, MYGN, GPRO - Company News And Updates From DrStockPick.com .
Posted by drstockpick on September 21st, 2010
Read More
comment 0
Share
Tags:
biotechnology, cancer, MYGN, pwrm.ob, cancer treatment, myrexis, myrx, tumor, breast cancer, Alzheimers, Power 3 Medical, proteomics, diagnostics, biopsy, genetic test, Ger Probe, Myriad Genetics, NASDAQ:GPRO, NASDAQ:MYGN, NASDAQ:MYRX, ovarian cancer, prostate cancer

ADVERTISE WITH US